Altimmune, Inc. (NASDAQ:ALT) Receives $14.33 Consensus Price Target from Analysts

Altimmune, Inc. (NASDAQ:ALT – Get Free Report) has received an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $14.3333.

Several brokerages recently issued reports on ALT. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research report on Wednesday, June 24th. Citizens Jmp decreased their price target on shares of Altimmune from $14.00 to $11.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 14th. HC Wainwright reiterated a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. Wall Street Zen raised shares of Altimmune from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Finally, Leerink Partners initiated coverage on Altimmune in a research note on Monday, June 22nd. They issued an “outperform” rating and a $10.00 price objective for the company.

Get Altimmune alerts:

Check Out Our Latest Stock Report on Altimmune

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. SBI Securities Co. Ltd. lifted its position in shares of Altimmune by 27.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock valued at $32,000 after acquiring an additional 1,928 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Altimmune by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock worth $247,000 after purchasing an additional 2,241 shares in the last quarter. Concurrent Investment Advisors LLC grew its position in shares of Altimmune by 10.4% during the fourth quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock worth $96,000 after purchasing an additional 2,500 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Altimmune by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock valued at $108,000 after purchasing an additional 2,748 shares during the period. Finally, Deutsche Bank AG raised its stake in Altimmune by 4.0% during the 4th quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock valued at $289,000 after purchasing an additional 3,047 shares during the period. Institutional investors own 78.05% of the company’s stock.

Altimmune Trading Up 6.1%

Shares of NASDAQ:ALT opened at $3.28 on Monday. The stock’s 50-day simple moving average is $3.01 and its two-hundred day simple moving average is $3.20. The stock has a market capitalization of $638.03 million, a price-to-earnings ratio of -4.21 and a beta of 0.18. Altimmune has a 52-week low of $2.56 and a 52-week high of $6.44. The company has a debt-to-equity ratio of 0.07, a quick ratio of 26.78 and a current ratio of 26.78.

Altimmune (NASDAQ:ALT – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 31.41%. Analysts expect that Altimmune will post -0.58 EPS for the current year.

About Altimmune

(Get Free Report)

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.

Featured Stories

• Five stocks we like better than Altimmune
• Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
• J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
• Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
• GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.